ABSTRACT-In animal models, administration of nitric oxide (NO) donor agents has been shown to reduce ischemia/ reperfusion (I/R) injury. Our aim was to systematically analyze the biomedical literature to determine the effects of NO-donor agent administration on I/R injury in human subjects. We hypothesized that NO-donor agents reduce I/R injury. We performed a search of Cochrane Library, PubMed, CINAHL, conference proceedings, and other sources with no restriction to language using a comprehensive strategy. Study inclusion criteria were as follows: (a) human subjects, (b) documented periods of ischemia and reperfusion, (c) treatment arm composed of NO-donor agent administration, and (d) use of a control arm. We excluded secondary reports, reviews, correspondence, and editorials. We performed a qualitative analysis to collate and summarize treatment effects according to the recommended methodology from the Cochrane Handbook. Twenty-six studies involving multiple etiologies of I/R injury (10 cardiopulmonary bypass, six organ transplant, seven myocardial infarction, three limb tourniquet) met all inclusion and no exclusion criteria. Six (23%) of 26 were considered high-quality studies as per the Cochrane criteria for assessing risk of bias. In 20 (77%) of 26 studies and four (67%) of six high-quality studies, patients treated with NO-donor agents experienced reduced I/R injury compared with controls. Zero clinical studies to date have tested NO-donor agent administration in patients with cerebral I/R injury (e.g., cardiac arrest, stroke). Despite a paucity of high-quality clinical investigations, the preponderance of evidence to date suggests that administration of NO-donor agents may be an effective treatment for I/R injury in human subjects.
INTRODUCTION
Ischemia/reperfusion (I/R) is a complex pathophysiologic process responsible for organ injury in a wide range of clinical conditions (e.g., myocardial infarction [MI] , organ transplantation, and cardiac arrest). Ischemia/reperfusion injury is a known contributor to morbidity and mortality in these conditions; however, no specific pharmacological treatment currently exists for the treatment of I/R injury.
Nitric oxide (NO) plays a pivotal and multifaceted role in the complex pathophysiology of I/R and has been implicated as a critically important mediator of I/R injury. Endogenous NO is released during the conversion of L-arginine to L-citrulline by NO synthase (NOS) (i.e., neuronal NOS, endothelial NOS [eNOS], or inducible NOS) (1) . Early in I/R injury, an increase in calcium uptake by endothelial cells leads to activation of eNOS and a rapid increase in NO production. This increase in NO production results in consumption of L-arginine and triggers eNOS uncoupling and a subsequent decrease in NO production by eNOS (2) . Although inducible NOS expression has been demonstrated to increase during I/R (3, 4) , NO generation by NOS is oxygen dependent and may be attenuated during ischemia (5, 6) . Several studies have found administration of NOS inhibitors during I/R injury to be detrimental (7Y9), leading many to believe endogenous NO is protective during I/R injury.
One of the main protective mechanisms is thought to be inhibition of reactive oxygen species (ROS) formation, which would otherwise lead to apoptotic signaling and cell death (10, 11) . Other potential mechanisms of protection include protein S-nitrosylation (12Y14) and activation of soluble guanylate cyclase (15Y18). Based on these mechanisms, exogenous NOdonor agent administration has been suggested as a potential treatment to increase cellular resilience to I/R injury. In animal models, NO-donor agent administration has been demonstrated to reduce I/R injury (11, 19Y30) . However, there is also the potential for deleterious effects of exogenous NO-donor administration; e.g., NO has also been demonstrated to play a key role in apoptosis through a reaction with superoxide to form peroxynitrite, which in turn induces tyrosine nitration and deleterious protein changes (31, 32) . These contrasting theories demonstrate that the dominant effects of NO in I/R remain unclear. Specifically, it is currently unclear if NOdonor agent administration reduces I/R injury in human subjects. If the available biomedical literature suggests that NO-donor agent administration may attenuate I/R injury in human subjects, this could serve as the scientific rationale for large-scale clinical trials of NO-donor agents to improve clinical outcomes in patients with I/R injury.
The objective of this report was to systematically review and analyze the biomedical literature of clinical investigartions testing the effects of NO-donor agent administration on I/R injury in human subjects. Our hypothesis was that administration of NO-donor agents before, during, or immediately after I/R is associated with reduced I/R injury.
MATERIALS AND METHODS

Search strategy
We performed a search of Cochrane Library, PubMed, CINAHL, and other sources using the following search terms: nitric oxide or nitrite or nitrate or nitroprusside or nitroglycerin or SNAP or SIN-1 or S-nitrosoglutathione or linsidomine or DETA or molsidomine or GEA or GNSO or nitrosothiol AND reperfusion, ischemia/reperfusion, or resuscitation. We modeled our search terms after search terms used in previously published systematic reviews of the effects of NO-donor agents on I/R injury in animal models (33, 34) . We did not include L-arginine (NO substrate) or hybrid donors (e.g., nitroaspirins, nicorandil), as we wanted to directly assess the effect of NO. We screened reference lists of all articles selected for inclusion to identify additional studies for potential inclusion. We also searched abstracts from the American Heart Association Resuscitation Science Symposium and the European Resuscitation Council Congress from 2010 and 2011. Finally, we consulted two independent experts in the field of I/R injury, to identify potential unpublished data. We considered studies eligible for review regardless of language or publication type, and we had all foreign language studies translated to English as needed.
Study inclusion and exclusion criteria
We included all human clinical studies of NO-donor agent administration during I/R, regardless of the route of administration (e.g., intravenous [i.v.], oral [p.o.], inhaled). Study inclusion criteria were as follows: (a) human subjects; (b) a documented period of ischemia (i.e., cessation of blood flow to at least one organ/body part); (c) a documented period of reperfusion following ischemia (i.e., return of blood flow to organ/body part exposed to ischemia); (d) an intervention arm in which subjects were administered an NO-donor agent (e.g., inhaled NO [iNO], sodium nitroprusside [NTP], nitroglycerin [NTG] ) as the single experimental intervention (we included all studies regardless of timing of administration of NO-donor [i.e., preischemia, intraischemia, or postischemia]); and (5) a clearly defined control arm in which subjects received placebo or standard-of-care therapy. We did not limit study selection to specific outcomes. We excluded studies that were secondary reports of previously published trials. We also excluded articles that were reviews, correspondence, or editorials; however, we screened the reference lists of review articles to identify further studies for inclusion.
Article selection and data extraction
Two reviewers (B.W.R. and J.M.) independently performed an initial relevance screen by reviewing the titles and abstracts of identified studies for potential eligibility. After the relevance screen, the two reviewers compared their logs, to identify any disagreement, and quantified the interobserver agreement using the . statistic. In cases of disagreement, a third reviewer (S.T.) assessed the abstract, and a consensus was reached between the three reviewers. All studies deemed potentially relevant were obtained, and the full manuscripts reviewed for inclusion. The original two reviewers (B.W.R. and J.M.) independently extracted data on all patient populations, interventions, outcome measures, adverse events, and results using a standardized data collection template. Any disagreements in these processes were resolved by consensus with a third reviewer (S.T.).
Study quality
We assessed the quality of all included studies using Cochrane Collaboration's tool for assessing the risk of bias in clinical trials (35) :
& Random sequence generation. In grade A, randomization sequence was adequately generated. In grade B, randomization sequence was inadequately generated. In grade C, randomization sequence was unknown.
& Concealment of allocation. In grade A, there was adequate concealment of treatment group allocation. In grade B, there was inadequate concealment of treatment group allocation; and in grade C, it was unknown. & Blinding. In grade A, investigators were blinded to treatment group allocation. In grade B, investigators were not blinded to treatment group allocation; and in grade C, blinding to treatment group allocation was unknown.
& Selective outcome reporting. In grade A, study was free of suggestion of selective outcome reporting. In grade B, there was suggestion of selective outcome reporting; and in grade C, selective outcome reporting was unknown.
As per the Cochrane Collaboration's tool for assessing the risk of bias in clinical trials, a high-quality study was defined as a grade of BA[ in at least three of four methodology domains mentioned (35) .
Analysis
We performed a primarily qualitative analysis of the data in accordance with the recommended methodology for qualitative reviews published in the Cochrane Handbook (35) . In table format, stratified by individual publication, we collated and summarized the following: (a) type of I/R (e.g., cardiopulmonary bypass, organ transplant); (b) NO-donor agent administered; (c) timing of administration (i.e., preischemia, intraischemia, or postischemia); (d) number of subjects in the treated and control groups; (e) outcome measures, including primary and all secondary outcomes, along with the associated effects of NO-donor agent administration on outcome measures compared with control treatment; (f) all adverse events reported and attributed to administration of NO-donor agent, including all serious adverse events; and (g) study quality (defined above).
RESULTS
Search and selection
The initial comprehensive search identified 6,694 potentially relevant articles, although most of these were excluded (Fig. 1) . After relevance screening (interobserver agreement . = 0.88), 6,654 studies were excluded secondary to (a) an NO-donor was not administered, (b) an NO substrate (e.g., L-arginine) or hybrid donor (e.g., nitroaspirins, nicorandil) was administered, or (c) the NO-donor was not administered to human subjects. A full manuscript review was performed on the remaining 40 articles. One full-length manuscript in German and two in Chinese were translated to English and determined to meet inclusion and no exclusion criteria, whereas one manuscript in Spanish translated to English failed to meet inclusion criteria. The primary reasons for study exclusion are shown in Table 1 . After full manuscript review, 26 studies were included in the final analysis, with a total of 1,557 subjects.
Study characteristics
The 26 studies were published over 27 years (1982Y2009). Ten studies examined I/R injury during cardiopulmonary bypass (Table 2) , six during organ transplantation (one liver transplant, five lung transplant) (Table 3) , seven during MI (two reperfused by percutaneous coronary intervention [PCI] , five reperfused by thrombolysis) (Table 4) , and three during application of limb tourniquets (one upper arm, one lower extremity, one forearm) ( Table 5 ). There were no human trials studying the effects of NO-donor agent administration in patients with cerebral I/R injury (e.g., stroke, cardiac arrest).
Ten studies administered iNO, eight administered NTP, four administered NTG, two administered isosorbide dinitrate, one administered potassium nitrate (KNO 3 ), and one study administered isosorbide mononitrate, NTG, and pentaerithrityl tetranitrate (PETN). Routes of administration included i.v., intracoronary, oral, inhaled, and transdermal, with timing ranging from one time bolus before ischemia, to continuous administration for 140 h after reperfusion. There was also significant variation in dosages used for each NO-donor agent (e.g., iNO 20Y80 ppm, NTP 0.1 2g I kg j1 I h j1 to 2 2g I kg j1 I min j1 , NTG 3 2g I kg j1 I min j1 to 2-mg bolus). Six (23%) of the 26 studies included were determined to be high-quality studies (two cardiopulmonary bypass, two organ transplant, and two MI studies). Overall, 20 (77%) of 26 total studies and four (67%) of six high-quality studies concluded that treatment with NO-donor agents reduced I/R injury compared with controls (Tables 2Y4) .
Cardiopulmonary bypass
Nitric oxideYdonor agents administered during cardiopulmonary bypass included iNO, NTP, and NTG. All 10 studies demonstrated attenuation of I/R injury by administration of NO-donor agents (e.g., decreased plasma inflammatory markers, reduced elevation of cardiac enzymes and creatinine, and improved cardiac index) ( Table 2) .
Organ transplant
Of the organ transplant studies included in this analysis, all administered iNO. One study administered iNO during liver transplantation and demonstrated that iNO produced faster resolution of elevated liver enzymes, decreased apoptosis, and shorter hospital stay compared with controls. Six studies administered (Table 3) .
Myocardial infarction
Nitric oxideYdonor agents administered during MI included iNO, NTP, NTG, and isosorbide dinitrate. In two of seven studies, PCI was the reperfusion intervention. One PCI study demonstrated an improved postreperfusion thrombolysis in myocardial infarction (TIMI) score among patients treated with 120 2g intracoronary NTP compared with controls. Although the second PCI study did not demonstrate a difference in TIMI score among patients treated with 60 2g intracoronary NTP, it did demonstrate a reduction in the 6-month rate of target lesion revascularization, MI, or death. In four (80%) of five studies, which used thrombolytics as the reperfusion intervention, the patients treated with NO-donor agents had reduced I/R injury compared with controls (e.g., decreased inflammatory markers, improved postreperfusion ejection fraction) ( Table 4) .
Limb tourniquets
Nitric oxideYdonor agents administered during application of a tourniquet included KNO 3 , iNO, NTG, PETN, and isosorbide mononitrate. All three studies demonstrated that NO-donor agents prevented I/R blunting of flow-mediated dilation (FMD) and decreased plasma inflammatory markers (Table 5 ).
Long-term outcomes
Only three studies followed patients' past hospital discharge. All three of these studies were in the setting of MI (Table 4) . One study found no difference in the incidence of angina at 1 month after reperfusion with thrombolytics in patients treated with isosorbide dinitrate compared with controls. The second study found a greater ejection fraction at 6 months after reperfusion with thrombolytics among patients treated with NTG compared with controls, and the third study found a decreased prevalence in target lesion revascularization, MI, or death 6 months after reperfusion with PCI among patients treated with NTP compared with controls.
High-quality studies
Six (23%) of the 26 studies included were determined to be high-quality studies according to the Cochrane Collaboration's tool for assessing the risk of bias in clinical trials; of these six studies, four (67%) concluded that treatment with NO-donor agents reduced I/R injury compared with controls: (i) Arom et al. (36) found in patients who underwent cardiopulmonary bypass that during the first 24 h after reperfusion zero patients developed atrial flutter or fibrillation, whereas 6 of 17 and 3 of 21 developed ventricular tachycardia in the placebo and NTP groups, respectively. During the 24-h to 10-day interval, 3 of 17 and 2 of 21 developed atrial flutter or fibrillation in the placebo and NTP groups, respectively, and 1 of 17 and 0 of 21 developed ventricular tachycardia in the placebo and NTP groups, respectively ( Table 2 ). They also found that intermittent injections of phenylephrine (Neo-Synephrine) were necessary in 5 of 17 patients in the placebo group (mean, 0.22 mg per patient) and 9 of 21 patients in the NTP group (mean, 0.29 mg per patient), to maintain the perfusion pressure greater than 50 mmHg as per the protocol. (ii) Kaya et al. (37) found in patients who underwent cardiopulmonary bypass that peak postoperative serum creatinine levels were significantly higher in the control group than in patients who received NTP (1.42 T 0.34 vs. 1.29 T 0.28 mg/dL). The prevalence of a 50% or greater rise in serum creatinine (35.3% vs. 13.7%) and development of a new creatinine clearance less than 50 mL/min (38% vs. 14%) during the first 5 postoperative days were significantly higher in the control group compared with the NTP group ( Table 2 ). (iii) Lang et al. (38) found in patients who underwent liver transplantation that those who received iNO had earlier resolution of posttransplant liver function test (i.e., transaminases and coagulation studies) elevations compared with the control group, as well as reduced hospital length of stay by 1.24 days (P = 0.034) when adjusted for sex and cold ischemic time. Reperfusion resulted in increased apoptosis (indicated by TUNEL staining) in both the placebo and iNO groups; however, the magnitude of increased TUNEL staining was significantly attenuated (~75%) in the iNO group (Table 3) . Methemoglobin levels rose continuously during iNO administration; however, they never rose to greater than 2%. Also, the volume of transfused platelets required during the surgical procedure was approximately 50% lower in the iNO group. (iv) Hildebrandt et al. (39) found in patients who received thrombolytics for MI that the peak CK-MB (creatine kinaseYmuscle, brain fraction) during the first 36 h after reperfusion was 306 and 471 U/L in the isosorbide dinitrate group and the control group, respectively. Among patients who achieved reperfusion, CK-MB was 419 and 369 U/L, and among patients who did not achieve reperfusion, CK-MB was 223 and 1,320 U/L in the isosorbide dinitrate group and the control group, respectively (Table 4 ). There was no difference in reported angina at 1 month between the groups (P = 0.68). Four patients in this study were withdrawn secondary to hypotension, and all were in the placebo group. (v) Meade et al. (40) found in patients who underwent lung transplantation that a PaO 2 /FIO 2 less than 150 was present on admission to the intensive care unit (ICU) in 14.6% and 9.5% of the iNO group and the control group, respectively. The groups had similar median times to first successful trial of unassisted breathing (25 vs. 27 h), successful extubation (32 vs. 34 h), ICU discharge (3.0 vs. 3.0 days), and hospital discharge (27 vs. 29 days). There were no differences in the multiple organ dysfunction score during the first 4 weeks after the transplantation (Table 3) . Methemoglobin levels did not rise to greater than 2%, and there were no adverse effects during the study that were felt to be directly attributable to the use or withdrawal of iNO.
(vi) Amit et al. (41) (Table 4) . There was also no difference in the median length of hospital stay between groups (6 vs. 7 days). At 6 months, the prevalence of major adverse cardiac events (i.e., death, recurrent acute MI, and target lesion revascularization) was 2 of 48 and 10 of 50 in the NTP group and the control group, respectively. A transient blood pressure drop to less than 90 mmHg systolic occurred in 3 of 48 and 0 of 50 of the NTP group and the control group, respectively.
Adverse events
Of the studies that reported on decrease in systemic blood pressure or increase in vasopressor requirements, 3 (38%) of 8 demonstrated worsening hemodynamic instability among patients administered an NO-donor agent. One study on postcardiopulmonary bypass patients reported that a higher proportion of patients administered NTP 2 2g I kg j1 I min j1 required vasopressor agent administration compared with controls (43% vs. 29%, respectively); however, two other cardiopulmonary bypass studies found no difference in vasopressor use between the treated and control groups at a lower dose of NTP (0.5 2g I kg j1 I min j1 i.v.) ( Table 2) . Two MI studies demonstrated transient hypotension in 6 of 71 total subjects treated with either NTP 60 2g intracoronary bolus or NTG 50 + 27 2g I min j1 i.v. for 24 h, and 0 of 70 in the control groups (Table 4) . None of the patients who developed transient hypotension had severe persistent hypotension. None of the included studies reported a plasma methemoglobin level greater than 2%. Among all included studies, there were no serious adverse events reported in the manuscripts.
DISCUSSION
In this report, we systematically analyzed the world's literature of clinical investigations testing the effects of NO-donor agent administration on I/R injury in human subjects. Our objective was to qualitatively describe the current literature to determine if administration of NO-donor agents during I/R appears to be a promising treatment of I/R injury. Among the 26 studies that met our inclusion and no exclusion criteria, we found that the preponderance of available evidence suggests that NO-donor agents can reduce I/R injury. In addition, none of the studies reported severe adverse events. However, given the paucity of high-quality studies, the heterogeneity of patient populations studied, and the heterogeneity of NO-donor agents utilized, this hypothesis requires rigorous further testing. Specifically, additional high-quality clinical trials (e.g., phase II trials) of NO-donor agent administration should be performed using a uniform treatment strategy in homogeneous populations of patients at risk for I/R injury, including assessment of long-term clinical outcomes. There are multiple mechanistic reasons why NO-donor agents could attenuate I/R injury (mechanisms summarized in Table 6 ). It is currently thought that I/R injury initiates its damage at the mitochondrial level. Ischemia/reperfusion injury can be characterized by two stages at the mitochondrial level. First was the ischemic phase, which causes a decrease in oxygen delivery and malfunction of the respiratory chain complex leading to anaerobic metabolism and inadequate ATP synthesis. Second, during the reperfusion phase, a sudden increase in oxygen delivery to the mitochondria leads to a dramatic increase in ROS production, which overwhelms the endogenous scavenging mechanisms. This sudden increase in ROS, along with calcium overloading, leads to the release of cytochrome c, which initiates apoptotic signaling and cell death (42Y44).
Nitric oxide has been shown to transiently inhibit complex I of the mitochondrial respiratory chain complex through S-nitrosation. Inhibition of complex I leads to a decreased electron flux through the respiratory chain and thereby a decrease in ROS generation (10) . Transient inhibition of complex I is important as irreversible inhibition would drastically inhibit ATP production, thereby counteracting cellular repair mechanisms, which depend on ATP for their function. Nitric oxide reduction of ROS generation has been demonstrated through administration of nitrite after I/R (11).
A second mechanism by which NO has been thought to be protective during I/R is through S-nitrosylation, which is a reversible, redox-dependent protein modification involving an NO moiety attachment to a thiol group (45, 46) . This covalent attachment has been proposed to alter the function of multiple proteins, resulting in reduced cell death through modification of intracellular calcium handling and regulation of apoptosis. S-nitrosylation has also been suggested to offer protection of thiol groups from irreversible oxidation damage during the initial period of reperfusion and then afterward allowing normal protein function to resume (12Y14). A third proposed protective mechanism of NO during I/R is through activation of soluble guanylate cyclase. Nitric oxide activation of soluble guanylate cyclase results in an increase in cyclic guanosine monophosphate (cGMP) levels. This increase in cGMP protects cells against I/R injury by modulating intracellular calcium handling and by opening mitochondrial ATP-sensitive potassium channels. These effects have been demonstrated in animal cardiac myocytes and postYcardiac arrest models (16Y18).
In addition to the effects described above, NO has been demonstrated to have other potentially beneficial physiological effects including (a) vasodilation, (b) inhibition of platelet activation, and (c) anti-inflammatory activities (47Y50). Although we believe vasodilation in the setting of I/R injury can potentially be of benefit by improving perfusion to ischemic tissue, there also exists the potential of induced hypotension and worsening perfusion. Human and animal data have demonstrated that NO-donor agent administration in sepsis improves microcirculatory blood flow (51Y53). Although we believe sepsis to be a distinct disease process from I/R injury and did not include it in this review, we believe there exists overlap in the pathophysiology of these disease processes, most notably dysfunction of the microcirculation (54); therefore, we believe the improvement in microcirculation seen in sepsis could also be applicable to I/R injury. A recent systematic review of clinical and in vivo preclinical data of NO-donor agent use in sepsis concluded that NO-donor agent administration may have potential benefit. The review also noted that reports of arterial hypotension were inconsistent, with only 6 of 17 animal studies and one of two clinical studies demonstrating a decrease in systemic blood pressure (34) . In this current report of I/R injury, of the studies that reported on decrease in systemic blood pressure or increase in vasopressor requirements, 3 (38%) of 8 demonstrated worsening hemodynamic instability in patients administered an NO-donor agent. All three studies reported that these effects were transient and treated successfully with vasopressors when needed. Further research is required to determine the macrocirculatory and microcirculatory effects of NO-donor agent administration in I/R injury.
Although there is evidence that NO may be protective during I/R, there also exists a body of literature suggesting that high levels of NO may actually be detrimental. During reperfusion, a sudden increase in oxygen delivery to the mitochondria leads to a dramatic increase in ROS production, most notably superoxide (55) . Under normal conditions, superoxide dismutase regulates the concentration of superoxide; however, during reperfusion-induced ROS overproduction, superoxide dismutase is overwhelmed. In high-enough concentrations of superoxide and NO, NO outcompetes superoxide dismutase and reacts with superoxide to form peroxynitrite (56) . Peroxynitrite induces tyrosine nitration of proteins, DNA, and lipids, resulting in deleterious structural and functional changes (31, 32) . Preclinical data on effects of decreased NO availability during I/R injury remain inconclusive. Several studies have demonstrated decreased NO availability (through genetic modification or administration of NOS inhibitors) to be beneficial (57Y59), whereas other studies have found administration of NOS inhibitors during I/R injury to be detrimental (7Y9).
In additional animal models of I/R injury, NO-donor agent administration was demonstrated to decrease infarction size and improve left ventricular function (11, 19Y22, 25) , decrease hepatocellular necrosis and apoptosis (11, 21, 23) , and attenuate renal injury (24) . A recent systematic review of NO-donor administration during animal stroke models identified 25 studies demonstrating an overall improvement in cerebral blood flow and a decrease in infarction volume (33) . In addition, in animal models of cardiac arrest, administration of an i.v. NO-donor agent or iNO was found to improve hemodynamics, resuscitation rates, and 24-h survival rates with good neurological function (18, 60, 61) .
We performed this study because we believe NO-donor agent administration could potentially attenuate I/R injury and improve clinical outcomes in patients with I/R. This report suggests that administration of NO-donor agents may be an effective treatment for many etiologies of I/R injury in human subjects. Of note, to date there have not been any human clinical trials testing the effects of NO-donor agent administration on cerebral I/R injury. We believe, given the available evidence summarized in this report, in conjunction with the preclinical animal data described above, further research on the effects of NO-donor agent administration on patients with I/R injury is warranted with the most evidence for further research in patients undergoing cardiopulmonary bypass.
We recognize important limitations in this systematic review. The main limitation is the fact that there were only 26 human clinical trials of NO-donor agent administration in I/R injury to date identified, and of these only six were determined to be high-quality studies according to the Cochrane Collaboration's tool for assessing the risk of bias in clinical trials; therefore, the results of the remaining 20 studies must be interpreted with caution. In addition, there were varying clinical scenarios, NO-donor agents, and clinical outcomes studied, resulting in a high degree of heterogeneity.
It is of importance to note that the varying NO-donor agents administered in the included studies have differing pharmacology and NO-donor capacity and therefore cannot be regarded as being the same. The six high-quality studies as well as the majority of the remaining 20 studies administered NTG, NTP, iNO, or isosorbide dinitrate. Nitroglycerin and isosorbide dinitrate are both organic nitrates, which react with thiols or other reducing substrates, and require metabolism by mitochondrial aldehyde dehydrogenase and other enzymes to form NO. Chronic use can lead to depletion of the reducing substances or inhibition for these enzymes and result in nitrate tolerance (62, 63) . The mechanism by which NTP releases NO has not been fully elucidated. Previously, it was believed that NTP spontaneously released NO; however, recently more complex mechanisms have been suggested including involvement of a tissue-specific membrane-bound protein or enzyme (64, 65) , or potential interaction with sulfhydryl-containing molecules (i.e., cysteine and glutathione) (66) . Inhaled NO has been suggested to be converted in the lung to transportable NO species, most notably nitrite (67, 68) . Subsequently, under conditions of ischemia, nitrite is reduced back to NO by various proposed catalysts (69Y75).
Also of note, ideal dosages or administration targets for each of these NO-donor agents in I/R injury have not been previously described, resulting in varying dosages and durations of treatment used. Because of paucity in high-quality studies, along with the high degree of heterogeneity, we could perform only a qualitative analysis of the current literature, and we were not able to perform a quantitative analysis or metaanalysis to determine the effects of NO-donor agent administration on any particular outcome. We also recognize that this systematic review may not have immediate applicability to clinical practice; however, our results are extremely important to clinical scientists who wish to pursue further investigation into methods of attenuating I/R injury.
In summary, there is a paucity of high-quality studies on the effects of NO-donor agent administration in patients with I/R injury, with no studies testing the effects of NO-donor agent administration on cerebral I/R injury in human subjects. We believe this paucity of high-quality studies is possibly secondary to concerns that administration of NO-donor agents to patients with I/R injury could potentially cause adverse events such as hypotension or methemoglobinemia. However, few adverse events were reported, and none of the studies reported severe adverse events. The available evidence suggests that administration of NO-donor agents may be safe and an effective treatment for many etiologies of I/R injury in human subjects. We believe that further clinical trials are warranted to determine the safety, feasibility, and efficacy of NO-donor agent administration in patients with I/R injury.
